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Background: MicroRNAs (miRNAs) are post-transcriptional regulators involved in numerous biological processes
including the pathogenesis of Alzheimer’s disease (AD). A key gene of AD, ADAM10, controls the proteolytic
processing of APP and the formation of the amyloid plaques and is known to be regulated by miRNA in hepatic
cancer cell lines. To predict miRNAs regulating ADAM10 expression concerning AD, we developed a computational
approach.
Methods: MiRNA binding sites in the human ADAM10 3' untranslated region were predicted using the RNA22,
RNAhybrid and miRanda programs and ranked by specific selection criteria with respect to AD such as differential
regulation in AD patients and tissue-specific expression. Furthermore, target genes of miR-103, miR-107 and
miR-1306 were derived from six publicly available miRNA target site prediction databases. Only target genes
predicted in at least four out of six databases in the case of miR-103 and miR-107 were compared to genes listed
in the AlzGene database including genes possibly involved in AD. In addition, the target genes were used for
Gene Ontology analysis and literature mining. Finally, we used a luciferase assay to verify the potential effect of
these three miRNAs on ADAM10 3'UTR in SH-SY5Y cells.
Results: Eleven miRNAs were selected, which have evolutionary conserved binding sites. Three of them (miR-103,
miR-107, miR-1306) were further analysed as they are linked to AD and most strictly conserved between different
species. Predicted target genes of miR-103 (p-value = 0.0065) and miR-107 (p-value = 0.0009) showed significant
overlap with the AlzGene database except for miR-1306. Interactions between miR-103 and miR-107 to genes
were revealed playing a role in processes leading to AD. ADAM10 expression in the reporter assay was reduced
by miR-1306 (28%), miR-103 (45%) and miR-107 (52%).
Conclusions: Our approach shows the requirement of incorporating specific, disease-associated selection criteria
into the prediction process to reduce the amount of false positive predictions. In summary, our method identified
three miRNAs strongly suggested to be involved in AD, which possibly regulate ADAM10 expression and hence
offer possibilities for the development of therapeutic treatments of AD.* Correspondence: wurst@helmholtz-muenchen.de; dietrich.truembach@
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MicroRNAs (miRNAs) are on average 22 nucleotides
long and play a pivotal role in gene regulation. These
small RNAs regulate the gene expression post-
transcriptionally by suppression of mRNA translation,
stimulation of mRNA deadenylation and degradation or
induction of target mRNA cleavage, but have also the
potential to activate translation [1,2]. Over half of the
mammalian protein coding-genes are regulated by miR-
NAs and most human mRNAs have binding sites for
miRNAs [3]. The interaction of miRNA and target
mRNA requires base pairing between the seed sequence
(positions 2–8) of the miRNA at the 50 end and a
sequence most frequently found in the 30 untranslated
region (UTR) of the target mRNA [4]. MiRNAs are
involved in neuronal functions like neurite outgrowth
and brain development. They were recently described to
play a role in human neurodegenerative diseases.
Changes in miRNA expression profiles or miRNA target
sequences could contribute to the development of
Parkinson’s disease and Alzheimer’s disease (AD) [5,6].
Characteristics of AD are insoluble plaques of amyloid
β (Aβ) peptides emerging from the cleavage of the amyl-
oid beta precursor protein (APP) and neuro-fibrillary
tangles in the brains of AD patients [7,8]. The alpha-
secretase “a disintegrin and metalloproteinase 10”
(ADAM10) [9-11] generates soluble secreted amyloid
precursor protein-alpha (sAPPα) and avoids formation of
plaques, because it cleaves APP inside the Aβ sequence
[12].
Numerous available computational methods predict a
large number of genes targeted by miRNAs regulating
gene expression, but only few have been validated ex-
perimentally. Many computational predictions are false
positives and therefore have to be filtered out [13]. The
requirement of target-site conservation in different spe-
cies including far related species would be a potential
way to reduce the false positive rate [14].
In this study we established an approach to identify
miRNAs regulating ADAM10 expression which there-
fore might influence the progression of AD. The three
programs RNA22, RNAhybrid and miRanda predicted
potential miRNA binding sites to ADAM10. We sought
to identify the most interesting miRNAs possibly binding
to ADAM10 with additional selection criteria in particu-
lar whether they play a role in AD. Additionally, the
most interesting miRNAs were experimentally verified
by a luciferase assay. Our results show that miR-103,
miR-107 and miR-1306 influence the expression of
ADAM10 at least in the reporter assay system. These
miRNAs could play a role in AD and therefore are inter-
esting candidates to be further analysed concerning their
biological function and relation to AD.Methods
miRNA target site prediction databases
MiRNA binding sites to target genes were downloaded
from seven different databases: miRBase, 5-Nov-2007,
http://www.mirbase.org/ [15]; microRNA, September
2008 Release, http://www.microrna.org/microrna/home.
do [16]; PicTar via UCSC Table Browser, assembly =
May 2004 (NCBI35/hg17), group = Regulation, track =
PicTar miRNA, http://genome.ucsc.edu/ [17]; PITA, ver-
sion 6 (31-Aug-2008), http://genie.weizmann.ac.il/pubs/
mir07/index.html [18]; RNA22, March 2007, http://
cbcsrv.watson.ibm.com/rna22.html [19]; TarBase, June
2008, http://diana.cslab.ece.ntua.gr/tarbase/ [20]; Tar-
getScan, Release 5, http://www.targetscan.org/ [3]. We
established a workflow considering all miRNA target site
predictions downloaded.miRNA target prediction
We used three prediction programs RNA22, RNAhybrid,
miRanda and predicted all binding sites of the miRNA
sequences to the 3'UTR sequence of human ADAM10.
RNA22 is a pattern-based method for the identifica-
tion of miRNA-target sites. The method has high sensi-
tivity, is resilient to noise, can be applied to the analysis
of any genome without requiring genome-specific
retraining and does not rely upon cross-species conser-
vation. Focusing on novel features of miRNA-mRNA
interaction RNA22 first finds putative miRNA binding
sites in the sequence of interest then identifies the tar-
geting miRNA and hence allows to identify sites targeted
by yet-undiscovered miRNAs. An implementation of
RNA22 (19-May-2008) is available online at http://
cbcsrv.watson.ibm.com/rna22.html [19,21].
The second program RNAhybrid is an extension of
the classical RNA secondary structure prediction algo-
rithm from Zuker and Stiegler [22]. It finds the energet-
ically most favorable hybridization sites of a small RNA
in a large RNA incorporating ‘seed-match speed-up’,
which first searches for seed matches in the candi-
date targets and only upon finding such matches the
complete hybridization around the seed-match is calcu-
lated. The user can define the position and length of the
seed region with the option to allow for G:U wobble
base pairs in the seed pairing. Intramolecular base pair-
ings and branching structures are forbidden and statis-
tical significance of predicted targets is assessed with an
extreme value statistics of length normalized minimum
free energies, a Poisson approximation of multiple bind-
ing sites, and the calculation of effective numbers of
orthologous targets in comparative studies of multiple
organisms. RNAhybrid, Version 2.1, is available online at
http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/ [23,24].
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Waterman algorithm, but scores based on the comple-
mentarity of nucleotides (A=U or GC) and one G:U
wobble pair is allowed in the seed region but has to be
compensated by matches in the 30 end of miRNA. In
order to estimate the thermodynamic properties of a
predicted pairing between miRNA and 30UTR sequence,
the algorithm uses folding routines from the Vienna 1.3
RNA secondary structure programming library (RNAlib)
[25]. A conservation filter is used and optionally some
rudimentary statistics about each target site can be gen-
erated. MiRanda, September 2008 Release, is available
online at http://www.microrna.org/microrna/home.do
[21,26].
The parameter setting for RNA22 is: maximum num-
ber of “UN-paired” bases within the extent of the seed =
0, extent of seed in nucleotides = 6, minimum number
of paired-up bases that you want to see in any reported
heteroduplex = 14, maximum value for the folding en-
ergy in any reported heteroduplex =−25 kcal/mol. The
parameter setting for RNAhybrid is: “-s 3utr_human”
(“-s” tells RNAhybrid to quickly estimate statistical para-
meters from “minimal duplex energies” under the as-
sumption that the target sequences are human 30UTR
sequences). The parameter setting for miRanda is
the default parameter setting: gap open penalty =−8, gap
extend =−2, score threshold = 50, energy threshold =
−20 kcal/mol, scaling parameter = 4.
We retrieved the 30UTR sequence of ADAM10 (human
ADAM10 30UTR based on transcript NM_001110
(chr15:58888510–58889745)) from NCBI http://www.
ncbi.nlm.nih.gov/. We downloaded 703 mature miRNA
sequences for Homo sapiens from miRBase, version 13.0
http://www.mirbase.org/ [15].
Extraction of best miRNA predictions
The extraction of miRNAs was applied according to the
following selection criteria. We checked for each miRNA
how many programs predicted the miRNA to bind to
human ADAM10 30UTR. The regulation of miRNAs in
AD was verified by the publication of Cogswell et al.
[27], which provides a list of miRNAs expressed in the
tissues hippocampus, cerebellum and medial frontal
gyrus. Another possibility to check the expression of
miRNAs in the brain is the Mouse Genome Informatics
(MGI) database (Mouse Genome Database, The Jackson
Laboratory, Bar Harbor, Maine; http://www.informatics.
jax.org/) [28]. Literature search by PubMed was done as
an additional approval, to search for already described
target genes of the miRNAs, especially for target genes
involved in AD. Mouse ADAM10 30UTR based on tran-
script NM_007399 (chr9:70625902–70628036) from
NCBI http://www.ncbi.nlm.nih.gov/ was used for bind-
ing site search of mouse miRNAs from miRBase, version13.0 http://www.mirbase.org/ [15]. The parameter set-
ting for RNA22 and miRanda is the same as for human
miRNA binding site prediction at the human ADAM10
30UTR. The parameter setting for RNAhybrid is “-d
1.9,0.28” (1.9 is the location parameter and 0.28
the shape parameter of the assumed extreme value
distribution). Additionally, we searched by TargetScan
database http://www.targetscan.org/ [3] and microRNA
database http://www.microrna.org/microrna/home.do [16]
for miRNAs binding to human ADAM10 30UTR and com-
pared the TargetScan and microRNA predictions to
our list of miRNAs for equal miRNAs. We identified the
number of binding sites of a miRNA in the human
ADAM10 30UTR predicted by each program. ADAM10
30UTR sequences from ten different species were analysed
for conserved regions. The following sequences where taken:
human ADAM10 30UTR from transcript NM_001110
(chr15:58888510–58889745), mouse ADAM10 30UTR
from transcript NM_007399 (chr9:70625902–70628036),
horse ADAM10 30UTR from transcript XM_001498169.1
(chr1:132875124–132876868), dog ADAM10 30UTR from
transcript XM_858910 (chr30:26596273–26598436), chimp
ADAM10 30UTR from transcript XM_001172393.1
(chr15:55942343–55944774), chicken ADAM10 30UTR
from transcript ENSGALT00000034458 (chr10:7949768–
7951846), rhesus monkey ADAM10 30UTR from tran-
script XM_001096908 (chr7:36929437–36932008), zebra
fish ADAM10 30UTR from transcript NM_001159314
(chr7:31745579–31747655), opossum ADAM10 30UTR
from transcript ENSMODT00000011088 (chr1:162230000–
162230183), zebra finch ADAM10 30UTR from transcript
XR_054746 (chr10:6638729–6639273). For multiple
sequence alignment of the ten ADAM10 30UTR
sequences we applied ClustalW Version 2.1 from the
European Bioinformatics Institute (EBI) http://www.ebi.
ac.uk/ [29,30]. We used default parameters except: DNA
Weight Matrix = ‘ClustalW’, Clustering = ‘UPGMA’. After
extraction of the conserved regions between at least
seven species we looked for miRNA binding sites
localized in these conserved regions. Additionally, we
determined the conservation (given in percentage)
of the miRNA binding site sequence from human to
each species.
Statistical analysis
Statistical analysis was performed with R statistical soft-
ware (R 2.8.0, http://www.r-project.org/). The p-value
was computed by the R function fisher.test with default
settings. The Fisher’s exact test is used to examine the
significance of the association (contingency) between the
two kinds of classification. Significantly regulated genes
were considered, if the p-value is equal or below 0.05.
We generated Venn diagrams to see the overlap between
target genes of miR-103 and miR-107 common in 4 out
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(http://www.alzgene.org/; Version: 20.06.2011) [31]. Each
set of target genes of miR-103 and miR-107 common in
4 out of 6 databases as well as the set of target genes of
miR-1306 in the database PITA was explored for enrich-
ment in Gene Ontology [32] by the software Pathway
Studio 8.0 (Ariadne Genomics) based on database
ResNet 8.0.Literature mining and pathway analysis
Literature search by PubMed was done to extract infor-
mation about the target genes of the miRNAs resulting
from Pathway Studio analysis and their relation to AD.
To verify the miRNAs searches were performed for
miRNA interactions in all PubMed abstracts with the
help of the text mining program Pathway Studio 8.0
(Ariadne Genomics) based on the Natural Language
Processing (NLP) Technology. Pathway analysis was
done with the software Ingenuity Systems IPA 9.0
(http://www.ingenuity.com/) especially with the Path
Designer.Material
Mature miRNAs and the inactive negative control were
from Invitrogen (No. PM11012, PM13206, PM10632,
PM10056). All RNA species were dissolved to 5 pmol/μl
in nuclease-free water upon arrival, aliquoted and stored
at −20°C.Cloning of the ADAM10 30UTR luciferase reporter
construct
The 30UTR of human ADAM10 was amplified from
THP-1 chromosomal DNA using the FailSafe PCR kit





The obtained DNA fragment was verified by restric-
tion digestion and sequencing. The 30UTR was subse-
quently cloned into the NotI site of the pCMV-GLuc
vector (NEB), which allows to monitor regulated Gaussia
luciferase expression in the cell supernatant.Cell culture
SH-SY5Y cells were cultivated in phenol red-free
DMEM/F12, supplemented with 10% FCS and 1% glu-
tamine at 37°C, 95% air moisture, 5% CO2 and passaged
twice a week with a splitting rate of ½ to ¼.30UTR luciferase reporter assay
Retro-transfection was performed using 0.005 μl Lipo-
fectamine 2000 (Invitrogen) per μl OptiMEM-medium
and 0.1 pmol/μl miRNA (Invitrogen) or negative control.
For combination of miRNA 1306 together with miRNA
103 or 107 a concentration of 0.05 pmol/μl each was
used. 2 ng/μl endotoxin-free plasmid DNA of the
30UTR-reporter vector were added to 45.000 cells per
well in 96 well format. Control cells were mock-treated
with nuclease-free water instead of RNA molecules.
5 hrs after transfection, the cell supernatant was
exchanged to 200 μl culture medium per well. In a pre-
liminary experiment, 10 μl cell supernatant were col-
lected at various time points over a 72 hour period;
48 hours were determined to be the optimal incubation
time (data not shown). Therefore, 10 μl cell supernatant
were aspirated 48 hours after transfection and stored at
−20°C until samples were measured. Secreted Gaussia
luciferase was quantitatively analyzed (Renilla-Luciferase
assay, Promega) using the FluostarOptima luminometer
(BMG). Cell densities were checked by quantitation




We established a workflow (Figure 1) to obtain miRNAs
possibly binding to the human ADAM10 30UTR. Instead
of looking up miRNA target sites of ADAM10 in the
miRNA target site prediction databases, we predicted
the binding sites of human miRNAs to human ADAM10
30UTR by the three programs, RNA22, RNAhybrid and
miRanda, with the aim to yield a more accurate miRNA
target site prediction. Due to the fact that the three pre-
diction programs focus on different aspects for miRNA
target site prediction (pattern-based search, seed match-
ing, conservation, energy or structure) various properties
of the target sequence are covered (see Methods:
“miRNA target prediction”).
122 miRNAs are predicted by at least two programs to
bind to human ADAM10 30UTR sequence and 52 of
them are significant according to expression and selec-
tion criteria described in the following. To consider dif-
ferent aspects of the distinct prediction algorithms at
least two programs should predict a miRNA binding site.
Important is also the expression of the miRNA in brain
provided by the MGI database or the regulation of the
miRNA in AD as described by Cogswell and colleagues
(2008) in the tissues hippocampus, cerebellum and
medial frontal gyrus [27]. An additional confirmation of
miRNA being involved in AD is a binding site to a target
gene, which is involved in AD, described in the literature
and thus the miRNA might regulate also other AD
key genes such as ADAM10. Furthermore, the miRNA
Figure 1 Computational prediction of miRNAs binding to
ADAM10 3'UTR. Three programs RNA22, RNAhybrid and miRanda
are used for the prediction of miRNAs binding to the human
ADAM10 3'UTR. After retrieving a list of 236 miRNAs by RNA22,
RNAhybrid or miRanda we extracted the relevant miRNAs according
to selection criteria: prediction by at least two programs, differential
regulation in AD patients (Cogswell et al. 2008), tissue-specific
expression (MGI), binding to AD key genes, corresponding mouse
miRNA binding to the mouse ADAM10 3'UTR sequence predicted
by at least two of the three programs, additional prediction by
TargetScan and microRNA, occurrence of multiple binding sites
and evolutionary conservation.
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miRNA binding to the mouse ADAM10 30UTR se-
quence predicted by at least two of the three miRNA
prediction programs RNA22, RNAhybrid and miRanda.
Prediction of the miRNA by other webtools such as
TargetScan and microRNA is also a confirmation of the
miRNA. Multiple binding sites of a single miRNA in the
30UTR verify the prediction [33].
The list of 52 miRNAs incorporates not conserved as
well as conserved miRNAs or rather miRNA binding
sites. Filtering according to conservation helps to reduce
the number of miRNAs and improves the selection of
candidates for further experimental validations. Consid-
eration of conservation across species, including those
not developing AD, was chosen as a filter criterion be-
cause a correlation between miRNA conservation and
disease susceptibility has in general been suggested by
Lu et al. [34]. Our selection procedure therefore
excludes non-conserved miRNA binding sites, which
also might be relevant for development of the disease
but are not lost by being included in the list of 52 miR-
NAs. In regard to AD being a human disease, future
analysis of non-conserved miRNAs might also represent
a valuable approach which we did not follow in thecontext of this manuscript. In our analysis eleven
miRNA binding sites are conserved across at least seven
species, at which four of these miRNAs are also con-
served in the far related species zebra fish. The only
miRNA binding site miR-1306 in the human ADAM10
30UTR predicted by all three programs is also conserved
in the far related zebra fish as well as in mouse, horse,
dog, chimp, chicken, rhesus monkey and zebra finch
(Figure 2A). This binding site is located on chromosome
15 positions 58889309–58889324 and the programs
RNA22, RNAhybrid and miRanda predicted the binding
energy −32.29, -25.7 and −22.55 kcal/mol, respectively.
The conservation of the miRNA binding site sequence
between human and the species mouse, horse, dog,
chimp as well as rhesus monkey is 100%. The conserva-
tion of chicken, zebra finch and zebra fish to human in
this binding region is 94%, 88% and 75%, respectively.
The second most interesting miRNAs possibly binding
to human ADAM10 30UTR are miR-103 as well as miR-
107 both having the same binding site located on
chromosome 15 positions 58889443–58889468. This site
is predicted by the two programs RNAhybrid and mi-
Randa with binding energy −27.9 and −23.66 kcal/mol
for miR-103, respectively, as well as −26.2 and
−22.28 kcal/mol for miR-107, respectively. The conser-
vation of the miRNA binding site sequence between
human and the species mouse, horse, dog and chimp is
96%, while the conservation of chicken, rhesus monkey
and finch to human is 65%, 100% and 73%, respectively
(Figure 2B–C). Additionally, miR-202, miR-423-5p, miR-
503, miR-184 and miR-922 bind also to the conserved
binding region chromosome 15 positions 58889443–
5889473 and miR-330-5p (chr15:58889149–58889178),
miR-671-5p (chr15:58889720–58889745) and miR-432
(chr15:58889688–58889718) bind to a region with good
conservation also to the far related species zebra fish,
but these eight miRNAs have no indication to be
involved in AD (Table 1). Table 1 shows a ranked list of
the best miRNA binding site predictions according to
the specific selection criteria. We chose the three most
interesting miRNAs 1306, 107 and 103 and performed
analyses with the AlzGene database, further miRNA
target site prediction databases, Gene Ontology, litera-
ture mining and validation experiments to identify the
involvement in AD. MiR-107 and miR-103 are downre-
gulated with age [35] as well as in AD gray matter [36]
and repress the translation of cofilin. In brains of a
transgenic mouse model of AD the level of miR-103 and
miR-107 is decreased while the cofilin protein level is
increased which results in the formation of rod-like
structures [37]. Furthermore, miR-107 expression is
decreased even in the earliest stages of AD. As miR-107
regulates beta-site APP-cleaving enzyme 1 (BACE1) it
might be involved in accelerated disease progression
Figure 2 Conservation of the three miRNA binding sites within the ADAM10 30UTR. The figure shows the conservation of the miR-1306 (A),
miR-103 (B) and miR-107 (C) binding region (light green) between different species. The blue sequence represents the miRNA binding to the DNA
of different species as listed on the left side. On the right side the conservation of the miRNA binding region (light green) from different species
to human sequence is given. Nucleotide mismatches in the binding region to human binding region are marked in red. The lines and colons
below the miRNA sequence show perfect nucleotide matches and G:U/T wobble pairs, respectively.
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age could concern a protective effect against plaque for-
mation because reduced levels of these miRNAs would
lead to an increased level of the predicted target
ADAM10 and its neuroprotective product sAPPα in
brains of AD patients. Our observations of stronginhibition (> 40%) of ADAM10 expression in the
reporter assay upon application of miR-103 and miR-107
would coincide with such a possible protective influence
on amyloid pathology (see “Experimental validation of
bioinformatically predicted miRNAs”). According to
the publication from Cogswell et al. [27] miR-103 is
Table 1 List of predicted miRNAs binding to a conserved region of human ADAM10 3'UTR
miRNA ; kcal/mol Confirmations Differential regulated in AD Conservation
zebra fish
1306 −26.85 predicted by 3 programs, mouse ADAM10 +
107 −24.24 targets BACE1, predicted by TargetScan, literature for AD,
mouse ADAM10
103 −25.78 predicted by TargetScan, literature for AD, mouse ADAM10 hippocampus, cerebellum
330-5p −27.20 predicted by microRNA, mouse ADAM10 hippocampus +
432 −22.81 predicted by microRNA cerebellum +
423-5p −22.1 mouse ADAM10 hippocampus, medial frontal gyrus
671-5p −27.61 mouse ADAM10 +
922 −27.99 predicted by microRNA
503 −25.41 predicted by microRNA, mouse ADAM10
202 −25.33 predicted by microRNA, mouse ADAM10
184 −23.33 mouse ADAM10
The best eleven predicted miRNAs, which bind to a conserved region of human ADAM10 3'UTR, are shown with additional information like the average predicted
binding energy in kcal/mol (column 2), verifications of the miRNAs from literature, by additional mouse ADAM10 prediction or other prediction programs
(column 3), the regulation of miRNAs in AD according to Cogswell et al. (column 4) and the conservation of the binding region in zebra fish marked with + in
the last column.
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in AD. In addition, the program TargetScan verifies the
same binding site of miR-103 and miR-107 to human
ADAM10. MiR-1306 is further analysed due to its good
conservation to the far related species zebra fish with
only one mismatch in the seed region. It is the only
miRNA whose binding site to human ADAM10 is pre-
dicted by all three programs RNA22, RNAhybrid and
miRanda, which strengthens the assumption that this
binding site is functionally active. Additionally as shown
in Figure 3 the hypothesis is verified that miR-1306
is associated to AD: Twelve predicted target genes
of miR-1306 are involved in processes and functions
playing a role in AD, the nervous system and otherFigure 3 Target gene predictions for miR-1306. Twelve target genes of
AD, brain, nervous system or other neurodegenerative diseases and graphi
the nucleus and the predicted target genes indicated by blue arrows and b
either in the nucleus, cytoplasm or membrane. The functions of the target
from Gene Ontology or Ingenuity Expert Findings, which are substantiatedneurodegenerative diseases. The predictions rely on
TargetScan while the dedicated functions are Ingenuity
Expert Findings or from Gene Ontology. MiR-1306 pos-
sibly regulates genes like the cholinergic receptor, nicoti-
nic, alpha 4 (CHRNA4), tumor necrosis factor receptor
superfamily member 1B (TNFRSF1B) and mitogen-
activated protein kinase kinase 4 (MAP2K4), which are
associated to AD by the functions frontotemporal
dementia, demyelination of neurons and Huntington’s
disease, respectively. MAP2K4 has been found to be
involved in AD and is putatively regulated by modules of
transcription factor binding sites [39]. Furthermore,
miR-1306 is located on chromosome 22 within the
second exon of DiGeorge syndrome critical region genemiR-1306 were predicted by TargetScan concerning their function in
cally interrelated by Path Designer (Ingenuity). The miRNA is located in
lue framed ellipses are located according to their Gene Ontology
genes are denoted by grey lines and grey framed ellipses and derived
by literature.
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being a subunit of the microprocessor complex [40]. Evers
et al. presents a case of a DiGeorge syndrome patient
with the typical deletion in chromosome band 22q11.2,
which contains DGCR8, suffering from dementia [41].
Prediction of miRNA target genes and their relation to AD
To confirm the relationship of the three miRNAs to AD
we searched for target gene predictions of these miRNAs
in the six databases miRBase, microRNA, PicTar, PITA,
RNA22, as well as TargetScan (Figure 4). The combin-
ation of different miRNA target site prediction databases
and the restriction of the output to four out of six data-
bases in the case of miR-103 and miR-107 are important
to reduce the amount of false positive miRNA target
sites in the end. In the case of miR-1306 there is no re-
striction of the output, because only the database PITA
incorporates predictions for this miRNA. Additionally,
Tarbase can be included in the analysis. The database
Tarbase has a special position, because in contrast to the
other six databases Tarbase contains experimentally sup-
ported miRNA targets and not in-silico predicted
miRNA binding sites. All miRNA target sites from Tar-
base are automatically included in the output of the ana-
lysis. In contrast to the other six databases Tarbase
doesn’t contain false positive miRNA target sites. In our
case Tarbase doesn’t contain target genes for the miR-
NAs: miR-103, miR-107 and miR-1306. The six miRNA
target site prediction databases miRBase, microRNA,
PicTar, PITA, RNA22, and TargetScan contain altogether
18915 different (according to EntrezGene) human genes
at which PITA alone contains 16819 genes. After the
analysis we got 156 and 157 target genes for miR-103
and miR-107, respectively, common in four out of six
databases, and 890 target genes for miR-1306 of databaseFigure 4 Workflow for miRNA target site prediction. Seven
databases miRBase, microRNA, PicTar, PITA, RNA22, TargetScan and
Tarbase, which is experimentally supported by miRNA targets, are
incorporated in the prediction of miRNA target sites. The input is a
miRNA and the output is a set of target genes common to four out
of six databases. Tarbase contains experimentally supported miRNA
targets and not in-silico predicted miRNA binding sites: all miRNA
target genes from Tarbase are automatically included in the output
of the analysis.PITA. As we focus on miRNAs playing a role in AD, we
used the AlzGene database to see which target genes
of the miRNAs have a genetic association with AD.
AlzGene database is a regularly updated aggregation of
all published genetic association studies including
GWAS (genome-wide association studies) performed on
AD phenotypes. 636 and 591 genes of AlzGene database
overlap with 18915 genes of the six miRNA target site
prediction databases and 16819 genes of database PITA,
respectively. The overlap between AlzGene database
genes and the target genes of miR-103, miR-107 as well
as miR-1306 are 12, 14 (Figure 5) and 24 genes, respect-
ively (Additional file 1). MiR-103 and miR-107 have 130
target genes in common (Figure 5, Additional file 1). Ap-
plying a Fisher’s exact test we got a p-value of 0.0065,
0.0009 and 0.1904 for the overlap of miR-103, miR-107
and miR-1306, respectively, with the AlzGene database,
which shows that 12 and 14 are significant high numbers
of overlapping genes between the target genes and the
AlzGene database. This result suggests that miR-103 and
miR-107 might play a role in AD. It is not remarkable
that the p-value for the overlap of miR-1306 with the
AlzGene database is not significant as the restriction to
four out of six databases was not possible, which conse-
quentially leads to the inclusion of a lot of false positive
target genes in the 890 target genes of miR-1306.
Gene ontology
Additionally, we did a Gene Ontology analysis with the
predicted target genes of the three miRNAs to validate
the functionality of the miRNAs and their involvementFigure 5 Venn Diagram. The Venn diagram shows the significant
overlap of the target genes of miR-103 and miR-107 common in four
out of six databases as well as the genes of AlzGene database.
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Pathway Studio we searched for molecular functions
and biological processes common to the target genes of
the three miRNAs. The molecular function calcium ion
binding is significant in all three miRNA analyses (miR-
103: p-value = 0.0011; miR-107: p-value = 0.0025; miR-
1306: p-value = 2.1 × 10−5) and is considered to be
involved in AD. Calcium ions are found in an elevated
level in tangle-bearing neurons of AD patients compared
to healthier neurons [42]. Further, an abnormal increase
of intracellular Calcium ion levels in neurites associated
with Aβ deposits was demonstrated in a mouse model of
AD [43]. An additional evidence is given by the signifi-
cant biological processes learning (miR-103: p-value =
0.0008; miR-107: p-value = 3.3 × 10−5; miR-1306: p-
value = 0.0003), brain development (miR-103: p-value =
0.0023; miR-107: p-value = 0.0004; miR-1306: p-value =
7.1 × 10−6) and nervous system development (miR-103:
p-value = 0.0004; miR-107: p-value = 0.0004; miR-1306:
p-value = 6.9 × 10−8) that the three miRNAs are involved
in AD. Mouse models with an overexpression of
ADAM10 showed a positive effect of the α-secretase on
learning and memory and mice with a dominant nega-
tive mutant form of ADAM10 had learning deficiencies
[12]. Environmental influences occurring during brain
development predefine the expression and regulation of
APP. As a consequence levels of APP and Aβ are
increased causing AD later in life [44]. The Aβ frag-
ments forming plaques are of varying length depending
on the site of cleavage. The Aβ42 fragment is a ligand for
the cellular prion protein, which is important for ner-
vous system development [45]. (See Additional files 2,
3 and 4: List of enriched target genes of miR-103/107/
1306 in Gene Ontology).
Literature mining
Furthermore, a network (Figure 6) containing already
published interactions of miR-103 and miR-107 with
genes involved in AD or included in the AlzGene data-
base was established using the literature mining tool
Pathway Studio. This network allowed confirming the
relation of the two miRNAs to AD by their respective
target genes. The genes dicer 1, ribonuclease type III
(Dicer) and TAR (HIV-1) RNA binding protein 2
(TARBP2) targeted by miRNA-103 and miRNA-107 are
components of the miRNA-processing complex [46]. Be-
sides those two genes, a link between the two miRNAs
is provided by linoleic acid [47], which probably affects
AD by increasing the expression of Presenilin1 (PSEN1)
and Aβ [48]. Another target gene in the network, Gran-
ulin (GRN), is regulated by miR-107 [49] which regulates
BACE1 as well [38]. Therefore both genes might be
involved in neurodegenerative diseases especially AD.
The tumor suppressors TP53 as well as TP73 appear toregulate the processing of miR-107 [46]. MiR-103
increases the expression level of fatty acid binding pro-
tein 4 (FABP4) while its expression is reduced by tumor
necrosis factor (TNF) [50]. All six target genes of the
miRNAs 103 and 107 GRN, BACE1, TP53, TP73, FABP4
and TNF are included in the AlzGene database, hence
putatively playing a role in AD. The four remaining
target genes cyclin-dependent kinase 2 (CDK2), cAMP
responsive element binding protein 1 (CREB1), nuclear
factor I/A (NFIA) and vascular endothelial growth factor
A (VEGFA) of the network are mentioned in literature
to be involved directly or in processes developing AD.
miR-103 directly binds and represses CDK2 and CREB1
through 30UTR binding [51]. CDK2 is a key regulator
in neuronal differentiation with the downregulation of
CDK2 as crucial event [52] and neuronal differentiation
is regulated by PSEN1, a major key gene of AD [53]. The
transcription factor CREB1 is involved in several types
of learning and memory. A direct involvement in AD
is seen in some mouse models, where its activity is
impaired [54]. NFIA is negatively regulated by miR-107
[55] and plays an important role in the formation of the
corpus callosum in the developing brain. The disruption
of NFIA results in agenesis of the corpus callosum [56],
whereas the size of the corpus callosum is significantly
reduced in AD patients [57]. The expression of the
hypoxia-regulated gene VEGFA is decreased by miR-107
[58]. Additionally, it is known, that polymorphisms
within the VEGFA promoter region are associated with
increased risk for AD, by reducing the neuroprotective
effect of VEGFA [59]. These findings of the literature
and AlzGene database confirm the biological role of the
target genes in neurodegenerative processes and hence
the involvement of miR-103 and miR-107 in AD.
Experimental validation of bioinformatically
predicted miRNAs
To demonstrate that the selected miRNAs 1306, 103
and 107 directly regulate ADAM10 expression by inter-
action with the 30UTR of the human gene, we performed
cotransfection experiments with a Gaussia reporter
vector harbouring the 30UTR of ADAM10 downstream
of the luciferase coding sequence together with the
respective miRNAs. As a positive control we used miR-
122 which has been identified and validated as an
important regulator of ADAM10 in hepatocellular
carcinoma by an experimental approach [60]. The pro-
grams RNA22, RNAhybrid and miRanda predicted a
miR-122 binding site to human ADAM10 30UTR with
binding energy −31.2, -25.6 and −21.84 kcal/mol (on
average: −26.21 kcal/mol), respectively, comparable to
the miR-1306 binding site prediction (see Results and
Discussion: “miRNA prediction”). Time resolved meas-
urement revealed that 48 hrs incubation period resulted
Figure 6 Interaction network of miR-103 and miR-107. The network (established by Pathway Studio) shows already published interactions
between miR-103 as well as miR-107 and genes known to be involved in AD or neurodegenerative processes. The different types of proteins or
small molecules are indicated by different symbols and the various interactions like regulation, expression and miRNA effect are also displayed
by various arrows.
Augustin et al. BMC Medical Genetics 2012, 13:35 Page 10 of 12
http://www.biomedcentral.com/1471-2350/13/35in maximal effects of the miRNAs in SH-SY5Y cells
(data not shown): while the negative control miRNA
had no impact on luciferase activity measured in the
cell supernatant, miR-122 reduced the luminescent sig-
nal to 57% as compared to water treated control cells
(Figure 7). This effect is even higher than the one
observed in the initial publication from Bai et al. (2009)Figure 7 Experimental validation of selected miRNAs. SH-SY5Y
cells were transiently cotransfected with the Gaussia reporter vector
harbouring the 3'UTR of ADAM10 downstream of the luciferase
coding sequence together with the respective miRNAs. MiR-122,
which has been described by Bai et al. [60] to target ADAM10,
served as a positive control. After 48 hrs of incubation, luminescence
was measured in the cell supernatant. Values obtained for control
(water) treated cells were set to 100%, data represent mean± SD of
three independent experiments performed in triplicate. *** P< 0.001,
ns = not significant, RLU= Relative Light Units.[60] but might be due to the different reporter enzymes
or cell lines used. The three miRNAs identified by bioin-
formatical approaches and integration of literature min-
ing all showed a significant decreasing effect on the
ADAM10 30UTR-reporter construct: miR-1306 lowered
the luminescent signal to 72%, miR-103 to 55% and miR-
107 to 48% of control. While miR-103 and miR-107 tar-
get the same DNA sequence within the ADAM10 30UTR
(see Figure 2), miR-1306 has a binding site in closer
proximity to the Stop codon. We therefore combined
miR-1306 and miR-103 or miR-107, respectively, but
observed no distinct significant synergistic effect (miR-
1306 vs. miR-1306/103 p < 0.001; miR-1306 vs. miR-
1306/107 p < 0.001). This might be due to the applied
concentration which was reduced to 50% in the combi-
nations (see methods “30UTR luciferase reporter assay”).
These experimental results suggest an influence of miR-
103, miR-107 and miR-1306 on ADAM10 expression.
Nevertheless, the biological impact of either miRNA has
to be elucidated further, e.g. by mRNA and protein mea-
surements. Assessing the effect of the selected miRNAs
on pathological features in AD mouse models would also
help to understand their distinct role in pathogenesis.
However, this study shows that the computational work-
flow consisting of prediction programs and specific
selection criteria is a suitable tool for the identification
of miRNAs influencing key genes of diseases such as
Alzheimer’s disease.
Conclusions
We established a computational approach for the identi-
fication of miRNAs putatively influencing the expres-
sion of ADAM10. A potential functionality of selected
miRNAs 103, 107 and 1306 was confirmed by 30UTR
luciferase reporter assay. These results show that the
evolutionary conservation of the target gene binding site
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from the disease for further experimental validation.
Moreover, these experiments underline the reliability of
our computational approach, which is a combination of
characteristics of the prediction software and specific se-
lection criteria for filtering out false positive predictions:
disease relevance, specificity of expression, evolutionary
conservation of binding sites and occurrence of multiple
binding sites. This workflow can also be applied to key
genes of other diseases with adjustment of the selection
criteria according to the scientific research interest. Our
approach provides a new selection tool for identification
and ranking of AD-related miRNAs, but to elucidate
a profound pathological role of selected candidates, fur-
ther experiments have to be done.
Additional files
Additional file 1: List of predicted target genes common in 4 out of
6 DBs. The table shows a list of predicted target genes of miR-103,
miR-107, miR-1306. These target genes are either listed in AlzGene DB
and target gene of at least one miRNA or target gene of at least two
miRNAs (column 3). Beside the gene symbol the Entrez GeneID is given.
Additional file 2: List of enriched target genes of miR-103 in Gene
Ontology. The table shows the Gene Ontology entities with enrichment
of predicted target genes of miR-103. Additionally a p-value and FDR
value is given.
Additional file 3: List of enriched target genes of miR-107 in Gene
Ontology. The table shows the Gene Ontology entities with enrichment
of predicted target genes of miR-107. Additionally a p-value and FDR
value is given.
Additional file 4: List of enriched target genes of miR-1306 in Gene
Ontology. The table shows the Gene Ontology entities with enrichment
of predicted target genes of miR-1306. Additionally a p-value and FDR
value is given.
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